In an evolving oncology landscape, biomarker-driven treatment decisions are crucial.

In 2021 there were over 17 updates to clinical guidelines for breast, prostate and ovarian cancer. Oncologists would have to read around 178 articles daily to keep up.

With best practice always changing, time-poor HCP’s face information overload. As a result, 52% of community oncologists don’t use biomarker testing to inform treatment.

We created ‘Mapping the Tumor’ as a solution to simplify this complex data by using a straightforward metaphor to highlight biomarker testing’s importance, better educate HCPs, and get patients the personalised treatment they need.